Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 6, 2010Journal of Clinical OncologyOpen Access

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMaría‐Victoria MateosUniversidad Complutense de MadridPRPaul G. RichardsonBroad InstituteRSRudolf SchlagUniversity of Würzburg

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mateos et al. (2010) studied this question.

synapsesocial.com/papers/6a0da59cfb8c7be8ffba77cchttps://doi.org/10.1200/jco.2009.26.0638
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Basal secretion of von Willebrand factor from human endothelial cells2008 · 141 citations
  2. 2Improved survival in multiple myeloma and the impact of novel therapies2007 · 2,265 citations
  3. 3Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study2008 · 51 citations
  4. 4DNA Double Strand Breaks Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity2008 · 5 citations
  5. 5Anti-CD3 Therapy Expands the CD4+CD25+ Compartment in Hemophilia a Mice Inducing Tregs That Potently Prevent Factor VIII Inhibitor Formation2008 · 6 citations